Pediatric HIV/AIDS Cohort Study (PHACS) 2020

项目概要/摘要 每年有超过100万感染艾滋病毒（PWLHIV）的孕妇接受抗逆转录病毒治疗 用于治疗和预防围产期及产后艾滋病毒传播的抗逆转录病毒药物，以及新的抗逆转录病毒药物 以快速的速度推出。虽然母亲使用抗逆转录病毒药物成功地减少了围产期艾滋病毒感染， 尽管抗逆转录病毒药物在子宫内传播的风险很小，但仍明显需要监测子宫内抗逆转录病毒药物对婴幼儿健康的安全性。 目前，全球有170万15岁以下的儿童感染艾滋病毒，其中绝大多数是围产期感染。 获得性艾滋病毒感染（PHIV）-他们正在进入青年期。在美国，疾病控制中心 美国疾病控制和预防中心（CDC）估计，2016年，美国有11，915人患有PHIV，其中包括1，814人 13岁以下的儿童和10 101名青少年和年轻人。艾滋病毒的终身影响 和抗逆转录病毒药物对他们的整体健康的影响是未知的，因为他们过渡到成年和成人艾滋病毒护理。 儿科艾滋病毒/艾滋病队列研究（PHACS）是一个网络，于2007年启动，目前由两个 前瞻性队列研究：ART毒性监测研究（SMARTT）， 4，000名婴儿、儿童和青年在围产期接触艾滋病毒但未受感染（PHEU）， 青少年主方案（AMP、AMP Up和AMP Up Lite）研究，随访1,000名患有 围产期艾滋病毒，并与PHEU的年轻成年人的比较队列。这些研究旨在回答 关于艾滋病毒感染和抗逆转录病毒药物暴露或治疗的短期和长期结果的问题。 PHACS 2020被设计为计划项目P01赠款，由以下四个支持核心组成： 科学管理核心（SAC），数据资源核心（DRC），健康教育和社区核心 （HECC）和流行病学和统计方法核心（ESC），以提供科学、研究中心和队列 基础设施、数据管理和分析、健康教育和社区投入，以及 为四个研究项目提供流行病学和统计支助：1）SMARTT; 2）青少年硕士 方案（AMP）UP系列（AMP UP系列）; 3）宫颈上皮内瘤变的自然史 (CIN)和人乳头瘤病毒（HPV）在接种HPV疫苗的青年人中的作用;以及TERBO 脑研究：情绪调节和行为结果的轨迹及相关脑区 和内在网络（TERBO BRAIN）。这种多学科、跨学科、跨学科和 协同P01将解决儿童、青年和年轻人接触的最关键的科学问题。 艾滋病病毒感染者或携带者。

Project Summary/Abstract Each year, there are more than 1 million pregnant women living with HIV (PWLHIV) who receive antiretroviral medications (ARVs) for treatment and perinatal and postnatal HIV transmission prevention, with new ARVs introduced at a rapid pace. Although maternal use of ARVs has successfully reduced perinatal HIV transmission, there remains a clear need to monitor the safety of in utero ARV for infant and child health. Currently, 1.7 million children under the age of 15 are living with HIV globally – the vast majority with perinatally acquired HIV infection (PHIV) - who are aging into young adulthood. In the US, the Centers for Disease Control and Prevention (CDC) estimates that in 2016, there were 11,915 persons with PHIV in the U.S, including 1,814 children younger than 13 years of age and 10,101 adolescents and young adults. The lifelong impact of HIV and ARVs on their overall health is unknown as they transition into adulthood and adult HIV care. The Pediatric HIV/AIDS Cohort Study (PHACS) is a network, initiated in 2007, currently consisting of two prospective cohort studies: The Surveillance Monitoring for ART Toxicities Study (SMARTT), with over 4,000 infants, children and youth with perinatal HIV exposure but who are uninfected (PHEU), and the series of Adolescent Master Protocols (AMP, AMP Up and AMP Up Lite) studies following 1,000 young adults with perinatal HIV, and a comparison cohort of young adults with PHEU. These studies are designed to answer questions regarding the short and long term outcomes of HIV infection and ARV exposure or treatment. PHACS 2020 is designed as a Program Project P01 grant, consisting of the following four support Cores: Scientific Administrative Core (SAC), Data Resources Core (DRC), Health Education and Community Core (HECC), and the Epidemiological and Statistical Methods Core (ESC) to provide scientific, site and cohort infrastructure, data management and analysis, health education and community input, as well as epidemiological and statistical support to four Research Projects: 1) SMARTT; 2) The Adolescent Master Protocol (AMP) Up Series (the AMP Up Series); 3) Natural History of Cervical Intraepithelial Neoplasia (CIN) and Human Papillomavirus (HPV) in HPV Vaccinated Youth with PHIV (HPV); and the TERBO BRAIN Study: Trajectories of Emotional Regulation and Behavior Outcomes and related Brain Regions And Intrinsic Networks (TERBO BRAIN). This multidisciplinary, interdisciplinary, transdisciplinary and synergistic P01 will address the most critical scientific questions for children, youth and young adults exposed to or living with HIV.